Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eribulin/encequidar - Athenex

Next Previous
Drug Profile

Eribulin/encequidar - Athenex

Alternative Names: Encequidar/eribulin - Athenex; Eribulin + HM-30181A - Athenex; Eribulin ORA; Eribulin oral/encequidar oral - Athenex

Latest Information Update: 15 Apr 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Athenex
  • Class 2 ring heterocyclic compounds; Amides; Antineoplastics; Benzopyrans; Cyclic ethers; Furans; Isoquinolines; Ketones; Macrocyclic compounds; Small molecules; Tetrazoles
  • Mechanism of Action Apoptosis stimulants; Cadherin modulators; Receptor protein-tyrosine kinase modulators; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 12 Sep 2023 Discontinued - Phase-I for Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)
  • 13 Feb 2023 Athenex terminates phase I trial in Solid Tumours in the US as per the sponsor decision(NCT04013217)
  • 28 Aug 2022 No recent reports of development identified for phase-I development in Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO, Liquid)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top